NovaBridge to Host Business Update Call to Review Phase 2a Data for VIS-101 in Wet AMD on Monday, March 9, 2026
MWN-AI** Summary
NovaBridge Biosciences (Nasdaq: NBP) will conduct a virtual business update call on March 9, 2026, at 9:00 AM ET, focusing on the Phase 2a clinical data for VIS-101, a promising treatment for wet age-related macular degeneration (wet AMD). VIS-101 is designed as a bispecific, tetravalent dual VEGF-A/ANG-2 inhibitor, aiming to outshine current therapies for patients with wet AMD, diabetic macular edema (DME), and retinal vein occlusion (RVO).
The update comes as VIS-101 completes a randomized, dose-ranging Phase 2a study, evaluating its efficacy and durability compared to existing treatment options. This initiative underscores NovaBridge's commitment to innovating therapeutic solutions in ophthalmology through its majority-owned subsidiary, Visara, which holds global commercialization rights for VIS-101 outside of Greater China and certain Asian regions, where Everest Medicines holds licensing agreements.
Key participants in the call will include NovaBridge CEO Sean Fu, MD, Emmett T. Cunningham, Jr., MD, PhD, MPH, co-founder of Visara, and Cadmus Rich, MD, MBA, Visara’s Chief Medical Officer. These industry leaders will share insights into the ongoing study and implications for patient care.
In addition to VIS-101, NovaBridge boasts a differentiated pipeline anchored by other candidates, including givastomig, which targets Claudin 18.2-positive cancers, and uliledlimab, an anti-CD73 antibody aimed at cancer immunotherapy.
Investors and the medical community can tune in to the live and archived webcast through the NovaBridge website, ensuring broad access to critical updates on advancements in innovative medicine. For more information, visit [www.novabridge.com](http://www.novabridge.com).
MWN-AI** Analysis
As NovaBridge Biosciences prepares for the virtual business update call on March 9, 2026, investors should closely monitor the anticipated Phase 2a clinical data for VIS-101, especially given its promising role as a dual VEGF-A/ANG-2 inhibitor aimed at treating wet age-related macular degeneration (wet AMD). This indication is significant, considering wet AMD represents a substantial market opportunity, with millions affected globally.
Investors can view this upcoming data as a pivotal moment for NovaBridge, particularly as VIS-101 emerges as a potential competitor to existing therapies. If results indicate superior efficacy or durability compared to current standard-of-care treatments, the implications could be transformative for the company's market positioning and revenue potential.
Notably, VIS-101’s global rights outside of Greater China, managed by NovaBridge's majority-owned subsidiary Visara, underscore its broad commercialization potential. Investors should watch for insights during the call regarding future strategic partnerships or licensing deals that may facilitate market entry in various regions.
Additionally, the development landscape surrounding wet AMD is competitive, but VIS-101's unique mechanism of action could prove advantageous. If the data showcases strong safety and efficacy profiles, investors might consider this an opportune entry point given the anticipated uptick in valuation post-announcement.
Moreover, as NovaBridge is diversifying its pipeline with other therapies, such as givastomig and ragistomig, a successful update for VIS-101 may also bolster confidence in the company’s broader strategy.
Overall, as clinical data emerges, investors should remain attentive to market trends and competitive intelligence that could affect NovaBridge’s stock value. Solid results and subsequent uptake in market interest could position the company favorably within a burgeoning biotech landscape.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
VIS-101, purpose-designed to be a best-in-class dual VEGF-A/ANG-2 inhibitor, has the potential to provide more effective and durable treatment than the current standard of care for patients with wet AMD, DME and RVO
Visara, a NovaBridge Majority-Owned Subsidiary, Holds Global Rights to VIS-101 Outside of Greater China and Certain Asian Territories
ROCKVILLE, Md., March 03, 2026 (GLOBE NEWSWIRE) -- NovaBridge Biosciences (Nasdaq: NBP) (NovaBridge or the Company) a global biotechnology platform company committed to accelerating access to innovative medicines, today announced that it will host a virtual business update call on Monday, March 9, 2026, at 9:00 AM ET to review Phase 2a clinical data for VIS-101 in patients with wet age-related macular degeneration (wet AMD).
VIS-101 is a purpose-designed, bispecific, tetravalent dual VEGF-A/ANG-2 inhibitor, designed to provide more potent and durable treatment benefits for patients with wet AMD, diabetic macular edema (DME) and retinal vein occlusion (RVO). VIS-101 is currently completing a randomized, dose-ranging Phase 2a study for wet AMD.
NovaBridge is the majority shareholder of Visara, Inc. (“Visara”). Visara holds global development and commercialization rights to VIS-101 outside of Greater China and certain other Asian territories, which are licensed to Everest Medicines.
Click here to register for the virtual webcast, which will begin at 9:00 AM ET.
Call Participants:
- Sean Fu, PhD, Chief Executive Officer of NovaBridge
- Emmett T. Cunningham, Jr., MD, PhD, MPH, Co-founder and Executive Chairman of Visara and Vice Chairman of the NovaBridge Board of Directors
- Cadmus Rich, MD, MBA, Chief Medical Officer of Visara
- Carlos Quezada-Ruiz, MD, FASRS, Chair of the Scientific Advisory Board of Visara
- Nikolas JS London, MD, FACS, Managing Partner, President and Director of Research, Retina Consultants San Diego
The live and archived webcast can also be accessed by visiting the News & Events page of the NovaBridge website. A replay of the webcast will be archived for at least 90 days.
About Visara
Visara is a clinical-stage biopharmaceutical company focusing on the development of best-in-class ophthalmic therapeutics. The Company is led by Co-Founder and Executive Chairman Emmett T. Cunningham, Jr., MD, PhD, MPH, a physician, innovator, entrepreneur, and investor and internationally recognized specialist in infectious and inflammatory eye disease. NovaBridge is the majority shareholder of Visara, and Visara controls global rights to VIS-101, outside of Greater China and certain countries in Asia.
About NovaBridge
NovaBridge is a global biotechnology platform company committed to accelerating access to innovative medicines. The Company combines deep business development expertise with agile translational clinical development to identify, accelerate, and advance breakthrough assets. By bridging science, strategy, and execution, NovaBridge enables transformative therapies to progress rapidly from discovery toward patients in need.
The Company’s differentiated pipeline is led by givastomig, a potential best-in-class, Claudin 18.2 x 4-1BB bispecific antibody, and VIS-101, a potential best-in-class bifunctional biologic, targeting VEGF-A and ANG2.
Givastomig conditionally activates T cells via the 4-1BB signaling pathway in the tumor microenvironment where Claudin 18.2 is expressed. Givastomig is being developed to treat Claudin 18.2-positive gastric cancer and other gastrointestinal malignancies. The product candidate is being evaluated in a global, randomized Phase 2 study, following the recent announcement of positive topline results from a Phase 1b, multi-center, open label study in first line gastric cancer. The Company is also collaborating with its partner, ABL Bio, for the development of ragistomig, a bispecific antibody integrating PD-L1 as a tumor engager and 4-1BB as a conditional T cell activator, in solid tumors. Additionally, NovaBridge owns worldwide rights outside of China to uliledlimab, an anti-CD73 antibody that targets adenosine-driven immunosuppression in cancer.
VIS-101 targets VEGF-A and ANG-2 to provide more potent and durable treatment benefits for patients with wet age-related macular degeneration, diabetic macular edema, and retinal vein occlusion. VIS-101 is currently completing a randomized, dose-ranging Phase 2a study for wet AMD. NovaBridge is the majority shareholder of Visara, Inc., and Visara controls global rights to VIS-101, outside of Greater China and certain countries in Asia.
For more information, please visit www.novabridge.com and follow us on LinkedIn.
NovaBridge Investor & Media Contacts
PJ Kelleher
LifeSci Advisors
+1-617-430-7579
pkelleher@lifesciadvisors.com
NovaBridge Biosciences
+1-240-745-6330
IR@novabridge.com
FAQ**
How does VIS-101 compare to existing therapies in terms of efficacy and durability for conditions like wet AMD, and what role does I-MAB IMAB play in the ongoing Phase 2a trial?
What specifically are the goals and anticipated outcomes of the upcoming Phase clinical data presentation for VIS-101, and how might I-MAB IMAB influence these results?
Can you elaborate on the potential market impact of VIS-101 in the ophthalmic therapeutics space, particularly in relation to I-MAB IMAB's strategic partnerships?
What are the next steps for VIS-101 following the completion of the Phase 2a study, and how does I-MAB IMAB fit into your commercialization plans for this therapy?
**MWN-AI FAQ is based on asking OpenAI questions about NovaBridge Biosciences Sponsored ADS (NASDAQ: NBP).
NASDAQ: NBP
NBP Trading
-4.45% G/L:
$3.459 Last:
500,956 Volume:
$3.40 Open:
